Dr. C.L. CHEUNG 張正龍
Memberships & EditorshipsMemberships:
- Committee Member of American Society of Bone and Mineral Research (ASBMR), United States
- Honorary treasurer of Osteoporosis Society of Hong Kong, Hong Kong
- Honorary treasurer of Institute of Cardiovascular Science and Medicine, Hong Kong
- Committee Member of Hong Kong Pharmacology Society, Hong Kong
Honours and Awards
- Early Career Award, Research Grants Council, University Grants Committee, Hong Kong, 2016
- Research Output Prize: Faculty of Medicine, the University of Hong Kong, 2013
- New Investigator Award: 2011 Joint conference of European Calcified Tissue Society and International Bone and Mineral Society, 2011, and
- Poster and Oral Presentation Awards from:
- Plenary oral presentation award, the 4th Seoul International Congress of Endocrinology and Metabolism, Seoul, Korea (2016)
- The 21st Medical Research Conference, the University of Hong Kong (2016);
- 9th Metabolic Syndrome, Type 2 Diabetes and Atherosclerosis Congress, Kyoto, Japan (2014);
- APSAVD-EMW Young Investigator Oral Award – Winner: 9th Congress of the Asian Pacific Society of Atherosclerosis and Vascular Diseases and 16th Diabetes and Cardiovascular Risk Factors – East Meets West Symposium, Hong Kong (2014);
- 19th Medical Research Conference, the University of Hong Kong (2014);
- 16th Annual Scientific Meeting of Institute of Cardiovascular Science and Medicine (2012);
- 2010 Annual Meeting of the Hong Kong Society of Endocrinology, Metabolism and Reproduction (2010)
Precision medicine is an emerging form of disease prediction, diagnosis, and prevention that uses genetics, biomarkers, and other personalized information to deliver the right treatment, to the right person, at the right time. As the underlying cause of disease could be different among patients, the use of Precision Medicine should both improve patient outcomes and deliver benefits to the health service, based on patient's individualized makeup. In addition, the use of information from research of precision medicine can also lead to new drug and biomarker discovery.
Currently, there are several strategic areas under the supervision of Dr. Cheung, including osteoporosis and sarcopenia, other endocrine disorders, and cancer.
Dr. Cheung is the prinicipal investigator of the Hong Kong Osteoporosis Study, a cohort study of osteoporosis that established in 1995 by Prof. Annie Kung. Together with the availability of other related omics (genome-wide genotyping and metabolomics with > serum 1000 metabolites) and big data, we are currently working in the following areas:
- Multiomics of osteoporosis;
- Development of fracture prediction algorithm;
- Development of novel supplement for improving bone and muscle health;
- Development of novel biomarker of osteoporosis and sarcopenia; and
- Pharmacoepidemiology of bone related diseases.
Other endocrine disorders
We have been working in other endocrine disorders, such as thyroid diseases and diabetes.
With the collaboration with several clinical oncologists, we have started developing risk prediction algorithm using big data coupled with advance machine learning approaches. We are particularly interested in cancers that are related to adverse bone outcomes, such as breast cancer, prostate cancer, and bone metastasis.
Development of precision medicine using integrative approach
(Endocrinology & Metabolism: 2016 ISI impact factor: 6.3; Percentile: 90.2) Moayyeri A*, Cheung CL* (*Co-first author), Tan KCB, Morris JA, Cerani A, Mohney RP, Richard JB, Hammond C, Spector TD, Menni C (2018) Metabolomic pathways to osteoporosis in middle-aged women: A genome-metabolome-wide Mendelian randomization study. Journal of Bone and Mineral Research (Accepted)
(Endocrinology & Metabolism: 2016 ISI impact factor: 6.3; Percentile: 90.2) Cheung CL* (*Corresponding author), Sing CW, Tang CSM, Cheng VKF, Pirmohamed M, Choi CH, Hung CS, Lau E, Lee KF, Mak MW, Leung J, Wong TW, Ho AYY, Chan KW, Hung V, Tam V, Siu SC, Sham PC, Cheung BMY, Wong ICK, Tan KCB, Kung AWC. (2016) HLA-B*38:02:01 Predicts Carbimazole/Methimazole-Induced Agranulocytosis. Clinical Pharmacology and Therapeutics;99(5):555-61
(Pharmacology & Pharmacy: 2016 ISI impact factor: 7.3; Percentile: 95.5) Cheung CL* (*Corresponding author), Lau KS, Ho AY, Lee KK, Tiu SC, Lau EY, Leung J, Tsang MW, Chan KW, Yeung CY, Woo YC, Cheung ENY, Hung VHF, Pang HK, Hung CS, Sham PC*, Kung AWC*. Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24.3. Nature Genetics;44:1026-1029
(Genetics & Heredity: 2012 ISI impact factor: 35.2; Percentile: 99.1)
- Cheung CL* (*Corresponding author), Tan KC, Kung AW. Cohort Profile: The Hong Kong Osteoporosis Study and the follow-up study. (2018) International Journal of Epidemiology. (Accepted) (Public, Environmental, and Occupational Health: 2016 ISI impact factor: 7.7; Percentile: 97.4)
- Lau WCY, Chan EW, Cheung CL, Sing CW, Man KKC, Lip GYH, Siu CW, Lam JKY, Lee ACH, Wong IC. (2017) Association between Dabigatran versus Warfarin and Risk of Osteoporotic Fractures among Patients with Nonvalvular Atrial Fibrillation. JAMA; 317(11):1151-1158 (Medicine, General & Internal: 2016 ISI impact factor: 44.4; Percentile: 98.4).
- Leung RYH, Han Y, Sing CW, Cheung BMY, Wong ICK, Tan KCB, Kung AWC, Cheung CL*(*Corresponding author). (2017) Serum 25-Hydroxyvitamin D and the risk of stroke in Hong Kong Chinese. Thrombosis and Haemostasis;117(1):158-163 (Peripheral Vascular disease: 2016 ISI impact factor: 5.6; Percentile: 91.2)
- Dalgaard K, Landgraf K, Heyne S, Lempradl A, Longinotto J, Gossens K, Ruf M, Orthofer M, Strogantsev R, Selvaraj M, Lu TTH, Casas E, Teperino R, Surani MA, Zvetkova I, Rimmington D, Tung YCL, Lam B, Larder R, Yeo GSH, O’Rahilly S, Whitelaw E, Penninger JM, Jenuwein T, Cheung CL, Ferguson-Smith AC, Coll AP, Körner A, Pospisilik JA (2016) Loss of Trim28 triggers bi-stable epigenetic obesity: Evidence for polyphenism in mouse and man. Cell; 164(3):353–364 (Biochemistry & Molecular Biology: 2016 ISI impact factor: 30.4; Percentile: 99.8)
- Cheung CL* (*Corresponding author), Lam KSL, Cheung BMY. (2016) Evaluation of cutpoints for low lean mass and slow gait speed in predicting death in the National Health and Nutrition Examination Survey 1999-2004. Journals of Gerontology series A-Biological Sciences and Medical Sciences;71(1):90-5 (Geriatrics & Gerontology: 2016 ISI impact factor: 6.0; Percentile: 96.7)
- Cheung CL* (*Corresponding author), Lam KSL, Wong ICK, Cheung BMY. (2014) Non-invasive Score Identifies Ultrasound-diagnosed Non-Alcoholic Fatty Liver Disease and Predicts Mortality in United States. BMC Medicine; 10;12:154 (Medicine, General & Internal: 2014 ISI impact factor: 7.3; Percentile: 94.5)
- Cheung CL, Tan KCB, Lam KSL, Cheung BMY. (2013) The relationship between glucose metabolism, metabolic syndrome, and bone-specific alkaline phosphatase: A structural equation modeling approach. Journal of Clinical Endocrinology and Metabolism;98(9):3856-63 (Endocrinology and Metabolism: 2013 ISI impact factor: 6.3; Percentile: 89.9)
- Cheung CL* (*Corresponding author), Lau KS, Sham PC, Tan KC, Kung AW. (2013) GREM2 is Significantly Associated with Bone Mineral Density in Southern Chinese. Journal of Clinical Endocrinology and Metabolism;98:E1557-61 (Endocrinology and Metabolism: 2013 ISI impact factor: 6.3; Percentile: 89.9)
- Cheung CL, Lam KSL, Cheung BMY. (2013) Beta-2 microglobulin is an independent predictor of all-cause and cardiovascular mortality among US adults. International Journal of Cardiology;168(5):4811-3 (Cardiac & cardiovascular systems: 2013 ISI impact factor: 6.2; Percentile: 91.6)
- Cheung CL, Livshits G, Zhou Y, Meigs JB, McAteer JB, Florez JC, Cupples LA, Demissie S, Kiel DP, Karasik D. (2010) Hip Geometry Variation Is Associated with Bone Mineralization Pathway Gene Variants: the Framingham Study. Journal of Bone and Mineral Research;25:1564-1571 (Endocrinology & Metabolism: 2010 ISI impact factor: 7.1; Percentile: 91.8)
- Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, Fraser WD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, Soranzo N, Bojunga J, Psaty BM, Lorentzon M, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Järvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hyppönen E, Spector TD (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study, Lancet;376;180-8 (Medicine, General & Internal: 2010 ISI impact factor: 33.6; Percentile: 99)
From 2014 to 2019: 9 grants as PI from 4 funding bodies, with the total funding over HKD$12M
- RGC (17104314): “Genetics and genomics of anti-thyroid drug induced agranulocytosis” 2014/2015 (HKD$905,558 for three years, PI)
- RGC/ECS (27100416): “Metabolomic Study of Osteoporosis in Southern Chinese” 2016/2017 (HKD$ 1,455,193 for four years, PI)
- NSFC/RGC joint grant (N_HKU729/16): “Identification of susceptibility genes involved in the pathogenesis and prediction of thyrotoxic periodic paralysis” 2016/2017 (HKD$956,480 for four years, PI)
- S.K. Yee Medical foundation grant (2161218): “Genetic screening service of HLA-B*38:02 in people prescribing antithyroid drug” 2016/2017 (HKD$899,708 for 2 years, PI)
- HMRF (05162796): “AKAP11 as a positive regulator of osteogenesis” 2017/2018 (HKD$1,198,862 for two years, PI)
- Beat Drug Fund (grant number NA): “A Comprehensive Program for Evaluation of Musculoskeletal Health and Pharmacist Medication Review” 2017/2018 (HKD$2,828,995.4 for three years, PI)
Seeking MPhil/PhD candidates:
The Department of Pharmacology and Pharmacy is inviting graduate students who are interested in conducting translational research in the area of "Pharmacogenomics and Precision Medicine" to join the Department. We are interested in the following research goals:
- To develop precision medicine for osteoporosis and related diseases and traits by combining lifestyle, clinical risk factors, biomarkers, and genetic/genomic risk factors. We are devoted to develop algorithms to predict disease risk, accurate diagnose, and optimize treatment for patients based on their personal, clinical, and genetic profiles.
- To avoid adverse drug reaction of commonly used medication by identification of the associated genetic marker(s). Screening of patients prior medication will help enhancing safe medication.
For further information about the project and suitability, please email Dr. Ching-Lung Cheung (email: email@example.com).
Current Group Members (2019)
- Dr. Chor-Wing Sing (Postdoctoral fellow)
- Dr. Gloria Li (Postdoctoral fellow)
- Dr. Raymond Leung (Technician)
- Ms. Donna Ng (Research pharmacist)
- Miss. Constance Mak (Research nurse)
- Mr. Vincent Cheng (PhD student)
- Ms. Pallas Chau (MPhil student)
- Ms. Jessica Wong (Part-time MPhil student/ pharmacist)
- Mr. Warrington Hsu (Part-time MPhil student/ statistician)
- Mr. Philip Au (Research assistant)
- Mr. Sam Lam (Research assistant)
- Mr. Ricky Wong (Research assistant)
L2-52, Lab Block, LKS Faculty of Medicine, 21 Sassoon Road, Pokfulam, Hong Kong